evipedia.ai
← Back

Celastrus paniculatus for Health & Longevity

Evidence Review created on 08/25/2026 using AI4L / Opus 5

Also known as: Jyotishmati, Jyothishmati, Malkangni, Malkanguni, Intellect Tree, Black Oil Plant, Climbing Staff Tree

Motivation

Celastrus paniculatus (also called Jyotishmati, Malkangni, or the intellect tree) is a woody climbing vine of the Indian subcontinent whose oily seeds have been taken for centuries as a brain tonic. Interest today centres on its reputation for sharpening memory and steadying mood, and on laboratory work suggesting the seed oil shields nerve cells from damage.

Classical Indian medical texts group the seeds among preparations meant to preserve mental clarity into old age, and the plant has since moved from that setting into the supplement market as a powder, capsule, or pressed oil. Almost everything measured so far, however, comes from animals and cell cultures rather than from people, and the vine is becoming scarce across parts of its native range.

This review examines what the available evidence shows about Celastrus paniculatus seeds and seed oil: how they are thought to act, which effects have been observed and in which species, what harms and contamination concerns have been documented, and how the preparations are dosed, sourced, and monitored in practice.

Benefits - Risks - Protocol - Conclusion

A short list of sources that give a substantial, high-level treatment of Celastrus paniculatus rather than a passing mention.

No content from the six priority platforms is listed because none of them has published on this plant; two independent search routes for each platform returned nothing relevant, which is consistent with the seed’s near-absence from Western clinical literature.

Grokipedia

  • Celastrus paniculatus

    Covers the botany, distribution, traditional preparations, and reported pharmacology in one place, and is useful for identifying the plant correctly against the other Celastrus species sold under similar names.

Examine

  • Celastrus paniculatus

    Gives the traditional seed-count titration used for dosing and states the key limitation directly: single doses do nothing, the effect builds over about two weeks, and human evidence is absent.

ConsumerLab

ConsumerLab has published no product review, warning, or dedicated report on Celastrus paniculatus. The compound appears on the site only incidentally, as one listed ingredient inside a broader answer about a multi-ingredient commercial nootropic formula, so no independent purity or potency testing of this seed is available from ConsumerLab.

Systematic Reviews

One systematic review of this plant is indexed on PubMed; no meta-analysis exists, because there are no randomised controlled trials (studies where participants are randomly assigned to treatment or control) to pool.

This intervention carries a clear trade-off between a claimed cognitive benefit and an unquantified safety profile, and the single available review covers both sides: it synthesises the pharmacological case and the toxicological record in the same document. There is no separate systematic review or meta-analysis dedicated to harms, and none is possible while human adverse-event data remain unpublished.

Mechanism of Action

Celastrus paniculatus seeds are dominated chemically by dihydro-β-agarofuran sesquiterpenes, a family of oily plant compounds, together with sesquiterpene alkaloids such as celastrine and paniculatine, plus sterols and linoleic-acid-rich fats. Three mechanisms are proposed, and they do not fully agree.

The first is cholinergic. Aqueous seed extract lowers brain acetylcholinesterase, the enzyme that clears away acetylcholine, the main memory-related signalling chemical, raising acetylcholine levels and improving retention in rats. Seed oil produced the same behavioural gain in a drug-induced amnesia model while cutting acetylcholinesterase activity.

The second is antioxidant and anti-inflammatory. Seed oil and alcohol extracts scavenge free radicals, raise catalase, glutathione and superoxide dismutase, the body’s own protective enzymes, lower malondialdehyde, a marker of fat damage, and suppress NF-κB (nuclear factor kappa B, the master switch for inflammatory gene activation), with falls in interleukin-6 and tumour necrosis factor-alpha.

The third is monoaminergic. Celastrus oil reduces the turnover of noradrenaline, dopamine and serotonin, the monoamines that carry mood and alertness signals, and the oil inhibits monoamine oxidase A, the enzyme that degrades them, while lowering the rodent stress hormone corticosterone.

The disagreement matters. One study found protection strongest in the fraction with the weakest antioxidant activity and no change in acetylcholinesterase at all, which points to a separate, still-unidentified constituent. Human absorption, tissue distribution, metabolism and half-life have never been measured for any of these compounds.

Historical Context & Evolution

The seeds enter recorded medicine through Ayurvedic, Unani and Siddha practice on the Indian subcontinent, where they are called Jyotishmati, roughly “possessed of light”. Classical use was not primarily cognitive. The oil was rubbed on joints for rheumatism and sciatica, swallowed for indigestion and as a purgative, and applied in skin disease, while the seeds were classed among the medhya rasayana, the preparations intended to preserve intellect into old age.

Laboratory interest began in the mid-twentieth century with Indian phytochemists isolating malkanguniol, malkangunin and the celapanin group of sesquiterpene alkaloids. The behavioural literature that turned the plant into a nootropic dates from the 1990s: passive-avoidance work at Kasturba Medical College reported markedly better retention in treated rats alongside a fall in brain monoamine turnover, an unexpected pairing that has never been fully reconciled with the cholinergic account. Work at the Walter Reed Army Institute of Research in the early 2000s then shifted attention to neuronal survival under oxidative and glutamate stress.

The plant reached Western supplement shelves through the do-it-yourself nootropic community rather than through clinical development, which is why its modern reputation rests on animal work. Nothing in that record has been retracted or overturned; what changed is the evidentiary standard applied to it. Reviews from 2021 onward still describe the preclinical case as compelling while noting that human trials remain absent.

Expected Benefits

High 🟩 🟩 🟩

No benefit of Celastrus paniculatus reaches this evidence level. High grading here would require controlled human trial data, and none has been published for any endpoint.

Medium 🟩 🟩

No benefit reaches this evidence level either. Every effect below rests on animal or cell-culture work, which caps the achievable grade.

Low 🟩

Memory and Learning Enhancement ⚠️ Conflicted

Rodents given seed extract or oil retain learned avoidance and solve mazes faster than controls in several laboratories. The proposed route is cholinergic, yet reports disagree: some find acetylcholinesterase inhibited, one found it unchanged, another found monoamine turnover reduced. Human data amount to one 1953 pilot.

Magnitude: Aqueous seed extract raised retention scores dose-dependently at 350 and 1050 mg/kg in rats and 500 and 1500 mg/kg in mice, measured against the reference nootropic piracetam at 100 mg/kg as the comparison standard (Bhanumathy et al., 2010), and seed oil reversed drug-induced memory deficits in the water-maze and object-recognition tasks (Faldu et al., 2023); the literature reports no standardised effect size for either comparison.

Anxiety Reduction

Seed oil reduced anxiety-like behaviour in the elevated plus maze in both healthy and chronically stressed rats, apparently through serotonin signalling rather than sedation, since motor activity and tolerance were unaffected. Evidence is entirely rodent; the one registered human anxiety trial has not reported results.

Magnitude: Celastrus oil at 1–1.5 g/kg produced significant anxiolytic (anxiety-reducing) activity with no sedation and no tolerance across repeated dosing (Rajkumar et al., 2007), and 400–600 mg/kg reversed restraint-stress anxiety behaviour (Bhagya et al., 2016); neither paper reports an effect size or percentage change.

Antidepressant-Like Effect

Seed oil shortened immobility in the tail-suspension and forced-swim tests in mice, matching fluoxetine. The proposed route combines monoamine oxidase A inhibition, dopamine and serotonin receptor involvement, and lower stress-hormone levels. Two independent groups replicated it, one alongside fluoxetine; no human depression data exist.

Magnitude: Half-maximal effective doses were 17.38 mg/kg in the forced-swim test and 31.62 mg/kg in the tail-suspension test, with efficacy comparable to fluoxetine (Valecha & Dhingra, 2016); a separate group replicated the effect under chronic unpredictable stress (Chahuan et al., 2023).

Neuroprotection Against Oxidative and Excitotoxic Injury

Seed oil and alcohol extracts kept cultured rat forebrain neurons alive under hydrogen peroxide and glutamate stress, and reduced neuronal loss in rodent models of aluminium exposure, mercury exposure, chemically induced epilepsy and Huntington-like striatal damage. All work is preclinical; the protective constituent has not been identified.

Magnitude: Pre-treatment attenuated hydrogen-peroxide and glutamate-induced neuronal death dose-dependently, raising catalase and lowering malondialdehyde (Godkar et al., 2006), with comparable histological rescue of cortex and hippocampus in aluminium-exposed rats (Chakrabarty et al., 2012); no study reports a percentage survival figure.

Speculative 🟨

Blood Lipid Reduction

A single rat study using methanolic seed extract at 65 mg/kg lowered total cholesterol, triglycerides and low-density lipoprotein while raising high-density lipoprotein (Patil et al., 2010). No replication and no human measurement exist.

Gastric Mucosal Protection

Seed oil at 200–400 mg/kg protected rat stomachs against alcohol- and indomethacin-induced ulcers and damped inflammatory signalling (Palle et al., 2018). The basis is one laboratory only, with no human data.

Lifespan Extension

A sesquiterpene-enriched seed fraction extended average survival of the nematode Caenorhabditis elegans by 23% (Fu & Zhao, 2020). The basis is an invertebrate model only, with no mammalian replication.

Analgesic and Anti-Inflammatory Effects

Alcoholic seed extract at 250–1000 mg/kg reduced pain responses and paw swelling in mice and rats (Kulkarni et al., 2015). The basis is a single laboratory, animal only, and the mechanism is unresolved.

Relief of Intestinal Spasm

A methanolic seed extract relaxed isolated rat and human ileum at sub-microgram concentrations (Borrelli et al., 2009). The basis is isolated tissue only, with no whole-organism or clinical confirmation.

Kidney Protection Against Heavy-Metal Injury

Ethanolic seed extract at 800 mg/kg limited lead-induced kidney damage in rats, preserving cell-survival signalling (Balaji et al., 2021). The basis is a single rat study, with no human measurement.

Antiproliferative Activity in Cancer Cells

A purified seed sesquiterpene suppressed the growth of cultured human breast cancer cells and triggered their self-destruction (Weng et al., 2013). The basis is isolated cells only, with no animal or human data.

Benefit-Modifying Factors

  • Genetic polymorphisms: No pharmacogenetic study exists. Because seed oil inhibits monoamine oxidase A, carriers of low-activity MAOA promoter variants, or of the slow COMT genotype (COMT clears dopamine in the frontal cortex), may already sit near the ceiling for any dopamine-driven gain.

  • Baseline biomarker levels: Rodent gains were largest where a deficit existed — oxidative stress, raised malondialdehyde, low glutathione. People with normal inflammatory markers have less headroom; those with raised high-sensitivity C-reactive protein (a blood marker of body-wide inflammation) plausibly have more.

  • Sex-based differences: Efficacy studies used male rodents almost exclusively, so female response is uncharacterised. The only clearly sex-specific finding in the whole literature is a harm rather than a benefit: suppression of sperm production in males.

  • Pre-existing health conditions: Benefit signals cluster in models of injury — chronic stress, chemically induced epilepsy, heavy-metal exposure, drug-induced amnesia. Healthy animals show smaller changes, so people who are already cognitively intact are the group most likely to notice nothing.

  • Age-related considerations: Ageing rats showed altered cerebellar trace-element handling that treatment shifted, and every neurodegeneration model used mature animals. Adults in their sixties and seventies are therefore the group the preclinical case addresses most directly, though none of that case is human.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches this evidence level. High grading would require controlled human safety data or post-marketing surveillance, and neither exists for this seed.

Medium 🟥 🟥

Heavy-Metal Contamination of Ayurvedic Seed Preparations

This seed reaches most buyers as an Ayurvedic powder or oil, a product category with a documented contamination problem. A randomised purchase of 193 Ayurvedic medicines sold online found one in five contained detectable lead, mercury or arsenic, and every contaminated product exceeded at least one acceptable daily intake limit. Contamination was as common in United States-manufactured as in Indian-manufactured products, and most contaminated items carried Good Manufacturing Practice claims. The risk travels with the supply chain rather than the plant.

Magnitude: 20.7% of 193 products contained detectable lead, mercury or arsenic, with a 95% confidence interval (the range in which the true value most probably lies) of 15.2–27.1%; preparations made by deliberately combining herbs with metals reached 40.6% (Saper et al., 2008).

Low 🟥

Gastrointestinal Irritation and Burning

The seed and its oil are described in classical texts as heating and purgative, and users report stomach burning, nausea and loose stools at higher intakes. Rodent work shows the oil slows gastric emptying and relaxes intestinal muscle, which fits the reported cramping. No controlled human tolerability data exist.

Magnitude: Not quantified in available studies. No controlled trial has ever recorded adverse-event rates for this seed in humans; the signal comes from traditional pharmacopoeia descriptions plus rodent work showing reduced gastric emptying (Palle et al., 2018) and potent relaxation of rat and human ileum (Borrelli et al., 2009).

Suppression of Sperm Production

An oily seed extract injected into rats every other day for a month emptied the testis germ-cell layer and arrested sperm formation. The authors framed this as a possible contraceptive use rather than an accident. Relevance to swallowed doses is unknown, and no human semen study exists.

Magnitude: Arrest of spermatogenesis with germ-cell depletion and vacuolisation at 0.2 mL of oily extract given into the abdominal cavity every other day for 30 days in adult rats (Bidwai et al., 1990); the report is histological and gives no sperm-count figure.

Liver Injury at High Injected Doses

The same rat experiment found focal liver-cell death at the doses that stopped sperm production. The lesions were absent 45 days after treatment ended, so the injury appears reversible. The route was injection rather than swallowing, which limits how far the finding transfers to supplement use.

Magnitude: Focal hepatic necrosis (patches of dead liver tissue) at 0.2 mL given into the abdominal cavity every other day for 30 days, with repair evident at 30 days and lesions fully resolved by 45 days after treatment (Bidwai et al., 1990); no enzyme values or incidence rate are reported.

Speculative 🟨

Sedation and Next-Day Dulling

Classical practice used the oil as a tranquilliser, and treated rats show reduced turnover of noradrenaline, dopamine and serotonin. The basis is mechanistic and traditional; no controlled human alertness measurement exists.

Serotonin Excess with Antidepressants

Mouse data show monoamine oxidase A inhibition plus serotonin receptor involvement — the combination behind serotonin syndrome (dangerous serotonin excess: agitation, fever, tremor) when stacked with antidepressants. No human case reported.

Pregnancy Loss

Indian folk practice used the seed both to bring on menstruation and to end pregnancy, and rodent anti-fertility activity is documented. No controlled reproductive-toxicity study covering pregnancy has been published for this species.

Risk-Modifying Factors

  • Genetic polymorphisms: No pharmacogenetic data exist. In theory, people carrying low-activity MAOA variants, or already taking serotonergic drugs, would reach a serotonergic ceiling sooner. This is inference from mouse enzyme data, not observation.

  • Baseline biomarker levels: Raised alanine aminotransferase or aspartate aminotransferase (liver enzymes released into blood when liver cells are damaged) before starting narrows the margin against the reversible liver injury rats showed at high injected doses.

  • Sex-based differences: The clearest documented harm is male-specific: germ-cell depletion and arrested sperm formation in rats. Female-specific risk is undefined, though traditional use of the seed to bring on menstruation argues for caution.

  • Pre-existing health conditions: Active peptic ulcer, erosive gastritis or uncontrolled reflux sits directly under the burning and purgative effects. Existing liver disease compounds the rodent hepatic signal. Bleeding and seizure disorders have no species-specific data.

  • Age-related considerations: Older adults carry more concurrent medication, so the sedative and serotonergic overlaps matter more. Age-related decline in liver and kidney clearance is untested here, because no human pharmacokinetic study has ever been run.

Key Interactions & Contraindications

  • Serotonergic antidepressants: SSRIs (selective serotonin reuptake inhibitors — sertraline, fluoxetine) warrant caution; MAOIs (monoamine oxidase inhibitors — phenelzine, selegiline) are an absolute contraindication, since the seed oil itself inhibits monoamine oxidase A. Consequence: serotonin excess. Mitigation: a 14-day gap after an MAOI is stopped.

  • Central nervous system depressants: Benzodiazepines (diazepam, lorazepam), sleep agents (zolpidem, eszopiclone), opioids and alcohol. Severity: caution. Consequence: additive drowsiness and impaired coordination. Mitigation: separation from evening dosing, and no driving until the combination has been tested at rest.

  • Cholinesterase inhibitors: Donepezil, rivastigmine, galantamine — dementia drugs that raise acetylcholine. Severity: monitor. Consequence: additive cholinergic effects such as nausea, cramping and slow pulse. Mitigation: separated dosing times, with prompt reporting of new digestive symptoms.

  • Lipid-lowering and blood-pressure drugs: Statins (atorvastatin, rosuvastatin) and antihypertensives. Severity: monitor. Consequence: additive lowering of low-density lipoprotein on rodent evidence. Mitigation: a repeat lipid panel at 12 weeks rather than blind adjustment of prescription doses.

  • Over-the-counter medicines: Sedating antihistamines (diphenhydramine, doxylamine) and motion-sickness agents add drowsiness; non-steroidal anti-inflammatory drugs (ibuprofen, naproxen) add stomach irritation to an already irritant oil. Severity: caution. Mitigation: dosing with food, separated by four hours.

  • Supplement interactions: Cholinergic stacks (alpha-GPC, citicoline, huperzine A) amplify nausea and cramping; serotonergic supplements (St John’s wort, 5-HTP, S-adenosylmethionine) amplify serotonin load; sedative supplements (valerian, kava, melatonin) amplify drowsiness. Severity: caution. Mitigation: one addition at a time.

  • Other intervention interactions: Multi-herb Ayurvedic formulas frequently already contain Jyotishmati, so adding a single-ingredient product duplicates the dose unknowingly. Severity: monitor. Consequence: unintended dose escalation. Mitigation: a full ingredient-panel check before products are combined.

Populations who should avoid Celastrus paniculatus:

  • Pregnant women at any stage, given traditional use of the seed to end pregnancy and documented rodent anti-fertility activity
  • Breastfeeding women, since no data exist on transfer into milk
  • Men attempting conception, or within one full sperm-production cycle (about 74 days) of a planned attempt
  • Anyone with active peptic ulcer, erosive gastritis, or uncontrolled reflux disease
  • Anyone with liver disease, alanine aminotransferase or aspartate aminotransferase above three times the upper limit of normal, or Child-Pugh Class B or C cirrhosis (moderate to severe liver failure)
  • Anyone taking a monoamine oxidase inhibitor, or within 14 days of stopping one
  • Children and adolescents under 18, for whom no dosing or safety data exist

Risk Mitigation Strategies

  • Heavy-metal certificate before purchase: A batch-specific third-party report showing lead, mercury, arsenic and cadmium below limits is the primary filter, since one in five products in this category tested positive. This directly addresses the contamination risk.

  • Low starting dose with slow titration: Cautious protocols start at roughly 250 mg of seed powder or five drops of oil daily for one week, doubling only if there is no burning or loose stool. This limits gastrointestinal irritation.

  • Dosing with food: Taking the dose at the end of a meal containing fat blunts the direct mucosal contact that drives the burning and nausea reported at higher intakes.

  • Semen analysis before extended use in men: For men who may want children, a baseline count and motility result banked before starting and repeated at six months tracks the arrested spermatogenesis observed in rats.

  • Liver enzyme check at eight weeks: A single alanine aminotransferase and aspartate aminotransferase measurement after two months catches the reversible hepatic injury signal early, while it is still reversible in the animal data.

  • No stacking with serotonergic agents: Complete separation of the seed from antidepressants, St John’s wort and 5-HTP removes the theoretical serotonin-excess pathway rather than attempting to manage it.

  • Single-ingredient products only: Avoiding proprietary blends prevents unknowing dose duplication and makes any adverse effect attributable to one ingredient rather than eight.

Therapeutic Protocol

  • Standard traditional protocol: Classical practice starts at ten whole seeds taken once daily, moving to fifteen and then twenty seeds if no adverse effect appears. This titration is the form recorded in Ayurvedic and Unani pharmacopoeias.

  • Modern supplement protocol: Commercial capsules supply 400–500 mg of seed powder or water extract, taken once or twice daily. Standardised extracts on the Western market are usually specified to a minimum polyphenol content.

  • Seed oil protocol: Pressed seed oil is taken at roughly five to ten drops, about 250–500 mg, with warm water or milk. This is the form used in the majority of the rodent behavioural work.

  • Competing approaches: Ayurvedic clinicians favour whole seed or pressed oil within a multi-herb formula; Western nootropic suppliers introduced the standardised single-ingredient extract. No comparison of the two has been run, so neither is the established default.

  • Who popularised each approach: The seed-count titration comes from the classical pharmacopoeias and is repeated in the modern Examine.com entry by Kamal Patel. The standardised water-extract format originated with Western nootropic vendors rather than with any clinic.

  • Best time of day: Morning with food is the conventional choice. The oil’s reported calming and monoamine effects have led some users to evening dosing instead. No study has compared timing, so the choice is empirical.

  • Half-life: Never measured in humans for any constituent. Rodent benefits required 14–30 days of daily dosing before appearing, which implies gradual adaptation or accumulation rather than an acute, single-dose action.

  • Single versus split dosing: Rodent protocols used once-daily dosing throughout. Splitting 500 mg into two smaller doses is common practice to reduce stomach burning, with no evidence that it changes the cognitive outcome.

  • Genetic polymorphisms and dosing: No pharmacogenetic guidance exists. People with slow COMT or low-activity MAOA variants have a theoretical reason to start at the lowest dose, given the monoamine oxidase A inhibition seen in mice.

  • Sex-based differences: No dose difference has been studied. Men planning conception have a specific reason to cap duration rather than dose, because the male reproductive finding was time-dependent over 30 days of exposure.

  • Age-related considerations: Protocols place adults over 65 at the lower end of any range, since concurrent medication is more common and the untested clearance question weighs more heavily with age.

  • Baseline biomarker influence: People starting with raised inflammatory and oxidative markers are the group in whom rodent models showed the largest shifts, so tracking those markers gives the best chance of detecting a real response.

  • Pre-existing conditions and dosing: For reflux, gastritis, or a history of liver enzyme elevation, the cautious options are complete avoidance of the oil form or the lowest powder dose, since both risks are dose-related in the available data.

Discontinuation & Cycling

  • Intended duration: Traditional use is a course rather than a lifelong habit, typically weeks to a few months within a rasayana regimen. No study has run beyond a few months in any species, so indefinite use is unstudied.

  • Withdrawal effects: None documented in humans or animals. Rodent anxiolytic work specifically reported no tolerance across repeated dosing, which argues against a rebound effect on stopping, though nobody has looked directly.

  • Tapering-off protocol: No taper is required on current evidence. Because no dependence or rebound has been described, stopping outright is the default; a one-week step down is reasonable only for the sedative-leaning oil form.

  • Cycling: Cycling is not needed for efficacy, since tolerance has not been observed. The practical reason to cycle is exposure limitation: eight to twelve weeks on, four weeks off, bounds cumulative contaminant intake and the male reproductive question.

Sourcing and Quality

  • Third-party heavy-metal testing: This is the single most important sourcing filter. A batch-specific certificate covering lead, mercury, arsenic and cadmium is the relevant document, because one in five products in the wider Ayurvedic category tested positive for at least one.

  • Correct species identification: Several Celastrus species and unrelated vines are sold under the same vernacular names. The distinguishing markers are the full binomial Celastrus paniculatus Willd. and, ideally, a botanical authentication or chromatographic identity statement.

  • Plant part and form: Only the seed and the oil pressed from it carry the pharmacological record. Leaf or stem material, which appears in cheaper products, has a different constituent profile and no behavioural evidence behind it.

  • Standardisation: Extracts specified to a stated polyphenol or sesquiterpene content are more reproducible than raw powder. No official standardisation marker has been agreed, so the specification is only as good as the supplier’s method.

  • Oil freshness and storage: The seed is roughly half oil by weight and rich in unsaturated fatty acids, so it turns rancid. Small quantities, a check for a sharp or paint-like smell, and cool dark storage all limit that.

  • Reputable suppliers: Established Western nootropic specialists such as Nootropics Depot publish batch identity and purity testing; Indian pharmacies licensed under AYUSH (India’s traditional-medicine regulator) are the mainstream alternative. Anonymous marketplace listings carry no such provenance.

  • Conservation status: Wild populations are declining and the species is listed as threatened in parts of its range, which raises both ethical and adulteration concerns. Cultivated-source declarations are preferable to wild-harvested material.

Practical Considerations

  • Time to effect: Nothing happens acutely. Rodent work needed roughly two weeks of daily dosing before behavioural differences appeared, and the Examine entry states directly that single doses are ineffective. A four-to-eight-week window is the realistic horizon for judging.

  • Common pitfalls: The frequent mistakes are expecting a same-day stimulant effect, escalating the dose when nothing happens within days, buying leaf rather than seed material, and stacking with several other cholinergic supplements so that nausea becomes unattributable.

  • Regulatory status: In the United States the seed is sold as a dietary supplement with no premarket efficacy or safety review. In India it is regulated as an Ayurvedic medicine under the AYUSH ministry. It is an approved drug nowhere.

  • Quality signal versus price: Cheap bulk powder is the main contamination vector; the price gap to properly tested material is small in absolute terms and is where the safety margin actually comes from.

  • Cost and accessibility: Neither expensive nor hard to obtain. Monthly cost typically runs well under the price of a common branded supplement, and both powder and standardised extract ship internationally without restriction.

Interaction with Foundational Habits

  • Sleep: Direction is potentiating toward sedation. The oil was used traditionally as a tranquilliser, and rodent data show reduced monoamine turnover, so evening dosing may deepen sleep onset but risks next-day dulling. Practical approach: a trial of the oil form on a non-working evening before it is adopted.

  • Nutrition: Direction is indirect and favourable. The seed is roughly half fat by weight, so absorption of its lipid-soluble constituents should improve when taken with a fat-containing meal. Taking it on an empty stomach is the main driver of the reported burning, so pairing with food is doubly useful.

  • Exercise: Direction is none established. No study has examined training adaptation, muscle protein synthesis, or performance with this seed. The one relevant mechanistic point is antioxidant activity, which in other supplements can blunt training-induced adaptation, so separating dosing from workouts by several hours is a conservative default.

  • Stress management: Direction is potentiating. Rodent work shows reduced corticosterone, the stress hormone, and reversal of restraint-stress deficits in memory and anxiety behaviour, so the effect should compound with breathwork, meditation or sleep regularity rather than substitute for them.

Monitoring Protocol & Defining Success

Before starting, the purpose of testing is not to prove the seed works — no human trial has defined a response marker — but to establish the two margins that animal data place under pressure: liver integrity and, for men, fertility. A useful baseline set covers alanine aminotransferase and aspartate aminotransferase, a fasting lipid panel, high-sensitivity C-reactive protein, and, where product provenance is uncertain, a blood heavy-metal panel. For men who may want children, a banked semen analysis precedes the rest.

Ongoing testing follows a simple cadence: the liver enzymes are repeated at 8 weeks, then at 6 months, then every 12 months while use continues. The lipid panel and inflammatory marker are repeated at 12 weeks to capture any drift. Blood metals are retested only where the product source changes or unexplained symptoms appear.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Alanine aminotransferase Under 25 U/L (men), under 20 U/L (women) Detects the hepatic injury seen in rodents at high doses Alanine aminotransferase is the liver-specific enzyme released when liver cells are damaged; conventional labs flag only above 40–55 U/L, which is far too permissive here. No fasting needed
Aspartate aminotransferase Under 25 U/L Confirms and contextualises any alanine aminotransferase rise Conventional labs report 10–40 U/L as normal, so the functional target is markedly tighter. Aspartate aminotransferase also rises with muscle damage, so a result drawn within 48 hours of hard exercise is uninformative. Best paired with gamma-glutamyl transferase (an enzyme of the bile ducts that rises with liver strain and alcohol intake)
Blood lead Under 1 µg/dL, ideally undetectable Screens for the documented contamination of this product category Best paired with blood mercury and urinary arsenic. Conventional occupational thresholds sit near 5 µg/dL and are not protective at this level of concern. Venous draw
Low-density lipoprotein cholesterol Under 100 mg/dL, and lower with existing cardiovascular risk Tracks the rodent lipid-lowering signal and any additive effect with statins Fasting 9–12 hours. Conventional reporting treats under 130 mg/dL as acceptable, which is looser than the functional target
High-sensitivity C-reactive protein Under 1.0 mg/L Tracks the anti-inflammatory claim, which is the plausible route to any felt benefit Invalid within two weeks of infection, injury, or hard training, all of which raise it spuriously. Best drawn fasting with the lipid panel
Total motile sperm count No established target for this use; track change from the individual’s own baseline Directly addresses the arrested spermatogenesis found in rats Requires 2–5 days of abstinence before collection. Only relevant to men; repeat at 6 months if use continues

Qualitative markers to track alongside the labs:

  • Recall of names, appointments, and where objects were left, ideally logged rather than remembered
  • Speed and ease of finding words in conversation
  • Baseline anxiety level and how quickly it settles after a stressor
  • Mood stability across the day and week
  • Sleep onset latency and morning alertness, since the sedative signal cuts both ways
  • Stomach comfort in the two hours after dosing, which is the earliest tolerance signal

Emerging Research

  • No registered trials on ClinicalTrials.gov: A registry search returned no studies naming this species or its synonyms Jyotishmati and Malkangni. The entire modern human pipeline for this seed therefore sits outside the United States registry system, which limits transparency about what is under way.

  • Jyotishmati versus sertraline in anxiety: A published protocol describes a double-blind equivalence trial in 70 adults comparing 500 mg capsules twice daily with sertraline over 60 days, using the Hamilton anxiety rating scale and serum cortisol. Registered in India as REF/2023/07/069880; no NCT ID exists.

  • Isolating the active constituent: Fu & Zhao, 2020 characterised eighteen new sesquiterpenes from the seed and showed three extended nematode survival. Identifying which single molecule carries the effect would move the field from a crude oil to a defined agent with measurable pharmacokinetics.

  • Parkinson’s disease models: Seed extract protected dopamine neurons against a chemical toxin in cell culture (Phattanakiatsakul et al., 2024) and against rotenone in zebrafish (Manoharan et al., 2025). Replication in a mammalian model would strengthen the neuroprotective case considerably.

  • What could weaken the case: The most recent systematic review (Kumar & Jaitak, 2026) states that randomised human trials are entirely absent and that quality standardisation is unresolved. A first negative human trial, or a pharmacokinetic study showing negligible absorption, would undercut the whole preclinical edifice.

  • Supply and authenticity pressure: Population-genetic work on threatened Thai stands (Kaenkham et al., 2025) documents fragmentation and declining diversity. Scarcity raises adulteration incentives, which is a research direction with direct consumer consequences rather than a purely botanical one.

Conclusion

Celastrus paniculatus is the oily seed of an Indian climbing vine, taken for centuries in a preparation meant to keep the mind clear and steady into old age. The modern case for it rests almost entirely on animals and cell cultures. Within those limits the findings are consistent and come from several independent laboratories: better performance on learning and memory tasks, less anxious behaviour without obvious sedation, mood effects resembling a standard antidepressant, and nerve cells surviving chemical stress. Effects on blood fats, the stomach lining, pain, and the lifespan of a laboratory worm each rest on a single study.

The human part of the record is all but empty. Nothing is known about how much of the seed reaches human tissue, how long it stays there, or what years of use would do. The harms on record are also from animals: halted sperm production and reversible liver damage at high injected doses, alongside the stomach burning that users describe.

A second problem sits outside the plant itself. Products in this category have a measured record of lead, mercury and arsenic contamination, and that risk travels with the supply chain rather than with the seed.

For someone weighing this against better-tested options, the honest summary is a well-replicated animal signal, an untested human profile, and a sourcing problem that is solvable but real.

Top - Benefits - Risks - Protocol